<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <ref-type name="Journal Article">17</ref-type>
      <contributors>
        <authors>
          <author>Jae-Suk Choi</author>
          <author>Joo Wan Kim</author>
          <author>Go-Woon Jung</author>
          <author>Dong-Chan Park</author>
          <author>Hyung-Rae Cho</author>
          <author>Sae Kwang Ku</author>
          <author>Jae-Hak Sohn</author>
        </authors>
      </contributors>
      <titles>
        <title>HYPOGLYCEMIC AND HYPOLIPEMIC EFFECTS OF β-GLUCAN DERIVED FROM AUREOBASIDIUM IN STZ-INDUCED DIABETIC RATS</title>
        <secondary-title>Journal of Animal and Plant Sciences</secondary-title>
        <alt-title>JAPS</alt-title>
      </titles>
      <dates><year>2018</year><pub-dates><date>2018/04/01</date></pub-dates></dates>
      <volume>28</volume>
      <number>2</number>
      <pages>660-668</pages>
      <isbn>1018-7081</isbn>
      <electronic-resource-num>NA</electronic-resource-num>
      <abstract>&lt;p&gt;The primary objective of the present study was to determine the effects of &amp;#946;-glucan derived from &lt;em&gt;Aureobasidium&lt;/em&gt; on diabetes and diabetic hyperlipemia in an animal model of streptozotocin (STZ)-induced diabetes. &amp;#946;-glucan was orally administered to STZ-induced diabetic hyperlipemic Sprague-Dawley (SD) rats for 4 weeks beginning at 25 days after STZ administration (late diabetic hypoglycemic and hyperlipemia model). Changes in body weight were recorded throughout the study and blood glucose and serum low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, and total cholesterol (T-CHOL) levels were measured at 28 days after &amp;#946;-glucan administration. The &amp;#946;-glucan results were compared with those from rats that received Simvastatin (10 mg/kg). Following the occurrence of STZ-induced diabetes, the STZ control group exhibited decreases in body weight and serum HDL levels in conjunction with increases in blood glucose, serum LDL, triglyceride, and T-CHOL levels compared to the intact control group. However, serum LDL, triglyceride, and T-CHOL levels dramatically decreased in the STZ groups that received &amp;#946;-glucan (62.5 and 125 mg/kg). The present results suggest that &amp;#946;-glucan derived from &lt;em&gt;Aureobasidium&lt;/em&gt; does not exert hypoglycemic effects in an SD rat model of STZ-induced diabetes. However, &amp;#946;-glucan did have favorable effects in terms of attenuating complications related to diabetic hyperlipemia at a dose of 62.5 mg/kg/day or more. Therefore, &amp;#946;-glucan may be a candidate as a novel hypolipemic agent designed specifically to treat diabetic complications related to hyperlipemia regardless of the severity of disease.&lt;/p&gt;</abstract>
      <keywords><keyword>Hypoglycemic effect, hypolipemic effect, β-glucan, rats</keyword></keywords>
      <publisher>Pakistan Agricultural Scientists Forum</publisher>
      <urls><related-urls><url>https://thejaps.org.pk/AbstractView.aspx?mid=2018-JAPS-240</url></related-urls></urls>
    </record>
  </records>
</xml>
